Closed · RFA-FD-14-023 · CFDA 93.103 · Discretionary

The Effect of Different Preparation Methods on the In Vitro and In Vivo Performance of Solid Dispersion Formulations (U01)

Federal grant opportunity posted by Food and Drug Administration, cataloged on Grants.gov.

$450K-$500K
Award range
Closed
Status
June 19, 2014
Close date
1
Expected awards

The verdict

The Effect of Different Preparation Methods on the In Vitro and In Vivo Performance of Solid Dispersion Formulations (U01) is a closed discretionary listing from Food and Drug Administration that offered $450,000 -- $500,000 across 1 expected award. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 481 other opportunities from Food and Drug Administration.

$450K-$500K
award range
Closed
application status
1
expected award
93.103
CFDA program

Archived opportunity record

The Effect of Different Preparation Methods o… is closed (last close June 19, 2014). The parent program page for CFDA 93.103 is the reliable place to catch re-announcements. Food and Drug Administration still indexes 481 other opportunities here.

According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.

Deadline tracker

Application window closed

Closed June 19, 2014

Posted Apr 18 Closes Jun 19

Est. Total Funding

$1,500,000

Expected Awards

1

Instrument

Cooperative Agreement

Description

Background: Solid dispersion has been investigated extensively to enhance bioavailability through improving dissolution property of poorly water-soluble drugs. In spite of the great potential for enhancing bioavailability using solid dispersion, the commercial application is limited and only a few products have been marketed so far, such as Prograf (Tacrolimus), Sporanox (Itraconazole), Kaletra (lopinavir/ritonavir). There are more and more approved and pending abbreviated new drug applications (ANDAs) referencing these products. For example, Tacrolimus is a calcineurin-inhibitor immunosuppressant indicated for Prophylaxis of organ rejection in patients receiving allogenic liver, kidney or heart transplants. Tacrolimus is practically insoluble in water (2-3 μg/mL) and several formulation approaches including solid dispersion, complexation with cyclodextrin, oily solution and others have been developed to improve drug availability. Of them solid dispersions succeeded in improving its delivery and led to commercialization. Itraconazole is a synthetic triazole antifungal agent, and is also practically insoluble in water. Itraconazole was formulated as amorphous solid dispersion in Sporanox, and there are two approved generic drug products. The concerns related to solid dispersion include but are not limited to drug substance crystallization during storage, drug substance precipitation from supersaturated solution during in vivo dissolution, and the impact of polymers on drug permeability in the gastrointestinal (GI) tract. Depending on how drug substance is converted from crystalline state to amorphous state, solid dispersion preparation can be roughly divided into two categories, i.e. solvent method and melting method. Solid dispersion carrier and manufacturing process for amorphous solid dispersion can affect not only solid dispersion stability, but also their in vivo or therapeutic performance. To keep drug substance from crystallization during storage as well as precipitation from supersaturated solution during dissolution, polymer carrier plays a critical role in solid dispersion formulation design. Different manufacturing processes impact not only the physical state of drug substance, but also the physical state of polymer carrier(s) including the miscibility of carrier with drug substance. Many techniques have been developed and applied on detecting the degree of crystallinity, such as powder x-ray diffraction (PXRD), infrared spectroscopy (IR), differential scanning calorimetry (DSC) as well as dissolution. However, it is still challenging to quantify the amorphous content in the formulation during manufacturing and storage, as the amount of amorphous material is generally measured indirectly through measuring the amount of crystalline material in the sample. It will be very valuable to identify and optimize analytical methods to detect solid dispersion quality changes during manufacturing and storage, and evaluate the impact of those changes on their in vivo performance. Regarding generic solid dispersion products, the FDA is interested in in vitro and in vivo performance of drug products made from different manufacturing processes, as well as their performance consistency during storage and among batches. This type of study would help establish optimal in vitro batch quality controls to ensure consistent batch to batch in vivo performance. Objectives: The objective of this study is to investigate the in vitro and in vivo performance for solid dispersion drug products made from different manufacturing processes or polymer carriers, as well as their performance consistency during storage and among batches. The investigation should identify critical process parameters and critical quality attributes for solid dispersion made from different preparation methods, and develop discriminating analytical methods. Detailed Descriptions: The following studies should be conducted for the purpose of this project: (1) Identify model drugs, and prepare amorphous solid dispersion using different preparation methods which include but not limited to solvent method and melting method. In addition, the impact of polymer miscibility with drug substance on the in vitro and in vivo performance of drug products should be taken into consideration when designing manufacturing processes. (2) Identify critical process parameters and critical quality attributes for solid dispersion made from different preparation methods, as well as discriminating analytical methods. The analytical methods should be able to detect drug product quality changes including crystalline content in amorphous solid dispersion and its impact on dissolution profiles, as well as precipitation of drug substance in the GI tract during dissolution. (3) Perform quality characterization on brand and generic solid dispersion drug products including assay, related substances, and dissolution in accordance with the United States Pharmacopeial (USP) standards (if available), and in discussion with the FDA (sponsor). (4) Determine stressed conditions that could result in significant quality changes including dissolution and precipitation changes. Evaluate the relationship between moisture content, crystalline content, and dissolution rate under stressed conditions and under long term storage. (5) Conduct a randomized, single dose, four-treatment, four-period cross-over in-vivo bioequivalence (BE) study in 24 normal healthy adult males and females (non-pregnant) (general population). Adverse events should be monitored and recorded through the study. Treatments including 1. RLD fresh 2. RLD aged (slower dissolution than RLD fresh) 3. Generic A fresh (slower dissolution than the RLD) 4. Generic A aged (much slower dissolution) Statistical analysis will be performed on the peak, partial and total exposure of drug product to determine if there are any significant pharmacokinetic differences among the RLD, generic drug products, and drug products from stability studies.

Wide-open applicant board · 15 Grants.gov doors

The Effect of Different Preparation Methods o… prints 15 distinct Grants.gov eligibility doors (State governments; County governments; City or township governments; Special district governments; +11 more). Filter fit before reading award size as demand — most applicant classes appear on the row. The extract does not mark applicant cost-sharing as required. Instrument: Cooperative Agreement. Funding-activity codes span Health · Science and Technology / R&D (HL;ST). 120 other Food and Drug Administration listings share this eligibility-code string (25% of 482).

Code 00
State governments
Code 01
County governments
Code 02
City or township governments
Code 04
Special district governments
Code 05
Independent school districts
Code 06
Public / state-controlled institutions of higher education
Code 07
Federally recognized tribal governments
Code 08
Public / Indian housing authorities
Code 11
Native American tribal organizations (other than Federally recognized tribal governments)
Code 12
Nonprofits with 501(c)(3) status (other than IHEs)
Code 13
Nonprofits without 501(c)(3) status (other than IHEs)
Code 20
Private institutions of higher education
Code 22
For-profit organizations other than small businesses
Code 23
Small businesses
Code 25
Others (see official listing text)

Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.

Official Listing on Grants.gov

View full details, application forms, and submission instructions.

View on Grants.gov

Agency Contact

Gladys Melendez-Bohler Grants Management Officer/Specialist Phone 240-402-7565

What to do next

The Effect of Different Preparation Methods o… is closed; use the parent program and agency catalog for the next funding cycle.

  • Parent CFDA 93.103 may publish future NOFOs under the same assistance listing. Open program
  • Food and Drug Administration Research indexes 42 Grants.gov listings in this extract. Program profile
  • Food and Drug Administration lists 481 other indexed opportunities on PlainGrants. Agency catalog

Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.

Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.

Data sourced from the SAM.gov Assistance Listings and Grants.gov. See our methodology for details. Retrieved and formatted by PlainGrants